Durvalumab Plus BCG Improves Disease-Free Survival in High-Risk Non-Muscle-Invasive Bladder Cancer

A subgroup analysis of the phase 3 POTOMAC trial revealed that the combination of durvalumab (Imfinzi) with BCG induction and maintenance therapy significantly improved disease-free survival (DFS) in patients with BCG-naive, high-risk, papillary-only non-muscle-invasive bladder cancer (NMIBC). These results were presented at the 2026 European Society for Medical Oncology (ESMO) Congress and published in The Lancet.